Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DAN-222 |
Synonyms | |
Therapy Description |
DAN-222 is a polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin, which may lead to inhibition of tumor growth (Cancer Res (2022) 82 (4_Supplement): P5-16-16). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DAN-222 | DAN 222|DAN222 | TOPO1 inhibitor 11 | DAN-222 is a polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin, which may lead to inhibition of tumor growth (Cancer Res (2022) 82 (4_Supplement): P5-16-16). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05261269 | Phase I | DAN-222 DAN-222 + Niraparib | A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer | Completed | USA | 0 |